Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ergomed LSE:ERGO London Ordinary Share GB00BN7ZCY67 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +3.00p +1.66% 184.00p 182.00p 186.00p 184.50p 180.00p 180.00p 20,000 12:39:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 54.1 -10.8 -20.0 - 84.94

Ergomed Share Discussion Threads

Showing 276 to 297 of 300 messages
Chat Pages: 12  11  10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
10/4/2019
01:38
Wonder if they will have to write off Haemostatix? No Phase 3 deal a year after supposedly great Phase 2 results - doesn’t sound good to me. Why don’t they do it themselves? Maybe they will if Multikine turns out to be a winner. It looks like Multikine is the last chance on the partnered drugs. The only other one was the Ferrer drug and like Haemostatix the Phase 2 results were touted as great but clearly they weren’t as no partners have been found to take the drug forward into Phase 3. CROs may be good at conducting trials but they seem to be poor at knowing whether the drugs will be winners.
jamtomorrow2
09/4/2019
15:33
Buys coming in. Let's see what tomorrow brings...
mfhmfh
06/4/2019
23:08
Interesting that Cel-Sci’s share price has doubled recently on optimism that Multikine’s trial will be successful. Ergomed has an interest in this drug.
jamtomorrow2
31/1/2019
14:41
Slater Investments Ltd above 10%
mfhmfh
21/1/2019
08:29
Oryx International Growth Fund above 8%
mfhmfh
22/11/2018
14:17
big volume today
mfhmfh
06/11/2018
15:37
Octopus bailing?
jamtomorrow2
31/10/2018
16:42
Agreed - thanks for the link
sicilian_kan
31/10/2018
16:02
They have certainly pushed up thier eps for this and next year. Looks rather interesting,
sidam
31/10/2018
15:07
Latest note from ED. https://www.equitydevelopment.co.uk/edreader/?ltkn=c39c859d40f5867e7315886ef7d8986aZlaE3Wj6&d=%3D%3DAO5QjM
edmonda
18/9/2018
10:13
Interim Results tomorrow
piedro
16/8/2018
09:12
AIM:ERGO - "building for growth" At the Full Year results, the new CEO Stephen Stamp outlined a value-enhancing vision for the business: a move away from co-development projects towards its existing Clinical Research Services (CRS) and its drug safety and medical information (DS&MI) businesses. Both the CRS and DS&MI businesses have been providing clear, repeatable project revenues and these markets are growing substantially. However, a number of issues have impacted business performance in the first six months of the year including the delay in the timing of a few key contracts and the lag effect of training up new staff to cope with the influx of expected work over the next few years. The former impacted revenues, the latter weighed on costs. Our FY2018 and FY2019 estimates have been trimmed to reflect the revised projections. Updating our valuation using peer-based metrics of c1.8x EV/Sales and c18x PE gives a fair value for the Services businesses (CRS and DS&MI) of 215p / share. The Development and Haemostatix businesses add a further 120p to that, based on an NPV (Net Present Value) analysis. Read the full note here ... https://www.equitydevelopment.co.uk/edreader/?d=%3D%3DQO1QjM
edmonda
01/7/2018
14:58
There is a recent report on Ergomed’s AGM which is available to read in our full member exclusive area here: hTTps://www.sharesoc.org/members-area/
sharesoc
29/6/2018
13:14
Ergomed to present to investors at the upcoming Proactive One2One Forum on 12th July in London. For details and registration, click here: https://tinyurl.com/ybq4tya2
aim_trader
28/6/2018
13:40
In a note to clients, analysts at Numis said that as Ergomed “is constantly hiring ahead of anticipated revenue growth”, a delay in anticipated revenue was going to drive margins lower as utilisation dropped. They added: “We downgrade our revenues by c.5% to £46.5mln primarily hitting the CRO division (£19.0mln from £21.6mln), with top line growth in PV [PrimeVigilance division] slightly higher, but on a higher cost base (reduced gross margins in both divisions) which effectively delays our EBITDA ramp by one year.” The broker was, however, fairly ambivalent regarding the delay: “Contract delays are a frequent occurrence in the CRO business, while in the PV division trading seems to have been in line with or slightly ahead of our expectations, while management planned for more.” hTTp://www.p roactiveinvestors.co.uk/companies/news/199777/ergomed-revenue-delay-leads-to-numis-downgrade-199777.html
sicilian_kan
28/6/2018
10:50
It is the companies second profits warning in the last year. Shares are now back to where they were a couple of months ago. I don't think you can complain you have been overly hard done by. The multiple is hardly cheap,
horndean eagle
28/6/2018
09:17
Yes, think disastrous RNS is probably a bit OTT - very disappointing more like it, especially given the Company's previous bullish statements.
bermudashorts
28/6/2018
09:12
what current market cap? Seems toppy..
tsmith2
28/6/2018
09:02
Mirabeau this isn't really a pharma stock. It is a CRO with a pharmacovigilance arm that it is expanding.
sicilian_kan
28/6/2018
08:46
What a mess. I only set up the thread and never held a position but how many pharma stocks in recent weeks have released seriously disastrous RNSs...too numerous to mention
mirabeau
28/6/2018
08:44
Seems completely overdone to me. - 5% reduction in revenue compared to market consensus, yet a 33% reduction in share price. - 2018 EBITDA still going to be ahead of 2017's £2.8m - Backlog of contracts still strong and increase on last years - The Company's cash position remains strong with positive cash flows in the period. I have only a small amount here. Invested 18 months ago on a 5 year basis. See no reason to bail out. Strategy and management still seem strong and am excited by the pharmacovigilance opportunities.
sicilian_kan
25/5/2018
16:44
Agreed and a nice rise too. I think we should be looking at testing 300p at some point in the coming weeks / months.
sicilian_kan
Chat Pages: 12  11  10  9  8  7  6  5  4  3  2  1
Your Recent History
LSE
ERGO
Ergomed
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190420 08:12:05